Forest’s LABA/LAMA Delay Gives GSK A Lengthy Lead On The Market

 
• By Jessica Merrill

News that Forest/Almirall’s LABA/LAMA combination will be delayed due to a manufacturing issue means that GlaxoSmithKline’s Anoro Ellipta will continue to dominate the market as the sole fixed-dose combination available in the U.S.

More from Approvals

More from Product Reviews